Interventional procedure overview of selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver

Interventional procedures

NICE interventional procedures guidance on melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. Recommendation: special for metastases in the liver from ocular melanoma; otherwise research only.

NICE interventional procedures guidance on selective internal radiation therapy for unresectable colorectal metastases in the liver. Recommendation: special arrangements for people who cannot tolerate chemotherapy or have liver metastases refractory to chemotherapy; research only for people who can have chemotherapy.

NICE interventional procedures guidance on selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma. Recommendation: research only.

NICE interventional procedures guidance on microwave ablation for treating liver metastases. Recommendation: standard arrangements.

NICE interventional procedures guidance on selective internal radiation therapy for primary hepatocellular carcinoma. Recommendation: standard arrangements.

NICE interventional procedures guidance on irreversible electroporation for treating liver metastases. Recommendation: research only.

NICE interventional procedures guidance on cryotherapy for the treatment of liver metastases. Recommendation: special arrangements.

NICE interventional procedures guidance on radiofrequency ablation for colorectal liver metastases. Recommendation: standard arrangements.

Technology appraisals

NICE technology appraisal guidance on selective internal radiation therapies for treating hepatocellular carcinoma. Recommendation: SIR-Spheres and Therasphere recommended as an option in a subgroup and with provision under commercial arrangements; QuiremSpheres is not recommended for use.

NICE technology appraisal guidance on lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours.

NICE technology appraisal guidance on everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease.